Outlook Therapeutics Q2 FY2026 net loss narrows to $4.5M; FDA decision on ONS-5010 expected May 2026

Outlook Therapeutics, Inc.

2026-Q2 EPS reported -$0.39

Net loss of $4.5M ($0.05/sh) vs $46.4M ($1.50/sh) YoY; adjusted net loss $14.1M ($0.16/sh).
LYTENAVA unit sales in Europe down ~10% QoQ; cost reduction steps initiated to improve margins.
Cash $7.7M as of Mar 31; raised ~$4M in March offering and $4.2M net in April registered direct offering.
FDA formal dispute resolution meeting completed in April; written decision expected within May 2026.
Entered Swiss distribution agreement with Mediconsult AG; targeting 2027 launch pending marketing authorization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Outlook Therapeutics, Inc. reported second fiscal quarter ended March 31, 2026 results: net income net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.

Period: second fiscal quarter ended March 31, 2026
Net income: net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share
Result: reported results

Exact text from the filing

Outlook Therapeutics reported net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-062865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.